A class action has been filed against Forest Laboratories, Inc. (NYSE:FRX), certain of its officers and directors by stockholders who purchased the company's common stock between August 15, 2002 and September 01, 2004. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. The stockholders seek to recover compensatory damages for the loss of value of their stock.

Forest Laboratories, Inc. and its subsidiaries, develop, manufacture and sell ethical drug products, which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter (OTC).

According to a press release dated March 11, 2005, a class action has been commenced on behalf of purchasers of Forest Laboratories, Inc. The complaint charges Forest Labs and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Forest Labs develops, manufactures and sells prescription drug products, as well as non-prescription pharmaceutical products.

The Complaint alleges that Forest Labs violated federal securities laws by issuing false or misleading public statements. Specifically, the Complaint alleges that Forest Labs concealed deficiencies with its Celexa/Lexapro drugs in treating adolescent depression and when Forest Labs ultimately disclosed an agreement with the New York State Attorney General to make available summaries of previously undisclosed studies on the drugs, the price of Forest Labs stock dropped to as low as $36 per share.

If you bought Forest Laboratories, Inc. securities between August 15, 2002 and September 01, 2004, inclusive, and would like to obtain information about the lawsuit, then you are invited to call (866) 467-1400 to speak with an attorney.